{"id":"invokana-pill","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Genital mycotic infections"},{"rate":"8-12","effect":"Urinary tract infections"},{"rate":"5-10","effect":"Polyuria"},{"rate":"3-5","effect":"Hypotension"},{"rate":"<1","effect":"Diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL2048484","moleculeType":"Small molecule","molecularWeight":"444.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 inhibitors work by blocking the reabsorption of filtered glucose in the proximal tubule of the nephron, allowing excess glucose to be excreted in the urine. This mechanism is independent of insulin secretion or action, making it effective across different stages of type 2 diabetes. The drug also provides cardiovascular and renal protective benefits beyond glucose lowering.","oneSentence":"Invokana (canagliflozin) inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:01.715Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Reduction of cardiovascular death and hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors"}]},"trialDetails":[{"nctId":"NCT06182839","phase":"PHASE2","title":"Canagliflozin in Advanced Renal Disease With MRI Endpoints","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-05-01","conditions":"ESRD, CKD Stage 4, CKD Stage 5","enrollment":92},{"nctId":"NCT06301529","phase":"PHASE4","title":"The Efficacy and Tolerability of Canagliflozin in Healthy Individual","status":"COMPLETED","sponsor":"AgelessRx","startDate":"2024-02-12","conditions":"Healthy Aging","enrollment":30},{"nctId":"NCT02624908","phase":"PHASE4","title":"Canagliflozin-Mealtime Insulin Rescue","status":"UNKNOWN","sponsor":"Foundation for Atlanta Veterans Education and Research, Inc.","startDate":"2016-01","conditions":"Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT02912455","phase":"PHASE4","title":"CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2017-01-05","conditions":"Diabetes Mellitus, Type 2, Obesity","enrollment":16},{"nctId":"NCT02920918","phase":"PHASE4","title":"Treatment of Diabetes in Patients With Systolic Heart Failure","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2016-10","conditions":"Heart Failure, Systolic, Diabetes Mellitus, Type 2","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Canagliflozin"],"phase":"marketed","status":"active","brandName":"Invokana Pill","genericName":"Invokana Pill","companyName":"AgelessRx","companyId":"agelessrx","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Invokana (canagliflozin) inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose. Used for Type 2 diabetes mellitus, Reduction of cardiovascular death and hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}